BMEA

BMEA

USD

Biomea Fusion Inc. Common Stock

$2.610+0.140 (5.668%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$2.470

Máximo

$2.650

Mínimo

$2.435

Volumen

2.30M

Fundamentos de la Empresa

Capitalización de Mercado

98.1M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

1.91M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $1.291Actual $2.610Máximo $13.07

Noticias Relacionadas

GlobeNewswire

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

PALM BEACH, Fla., June 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The Retinal and Fundis Camera market has shown growth in the recent years and is expected to continue for years to come. Fundus

Ver más
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities
Analyst Upgrades

Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7

Piper Sandler analyst Edward Tenthoff assumes Biomea Fusion with a Overweight rating and announces Price Target of $7.

Ver más
Piper Sandler Assumes Biomea Fusion at Overweight, Announces Price Target of $7
Analyst Upgrades

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion with a Buy and maintains $16 price target.

Ver más
D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target
GlobeNewswire

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the

Ver más
Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia